GRAND RAPIDS, Mich., July 17, 2026 (GLOBE NEWSWIRE) -- July 17, 2026. Meritage Hospitality Group Inc. (OTCQX: MHGU), one of the nation’s premier franchise operators, today reported financial results for the second quarter ended June 28, 2026.
CHARLOTTE, N.C., July 17, 2026 /PRNewswire/ -- Bank of America Corporation today announced the Board of Directors has authorized regular cash dividends on the outstanding shares or depositary shares of the following series of preferred stock: Series of Preferred Stock Dividend per Share...
Helport AI received a standard Nasdaq notification regarding the minimum bid price requirement, with no immediate impact on its Nasdaq listing.
PITTSBURGH, July 17, 2026 /PRNewswire/ -- Matthews International Corporation (NasdaqGSM: MATW) today announced plans to release its third quarter fiscal year 2026 earnings results after the market closes on Thursday, August 6, 2026 The Company will host a conference call and webcast to...
Dies ist eine Pressemitteilung der NNS Holding (Cyprus) Limited („NNS" oder der „Bieter"). Diese Pressemitteilung wird gemäß den Bestimmungen von § 5 Abs. 4 des niederländischen Erlasses über öffentliche Übernahmeangebote (Besluit openbare biedingen Wft) (das „Dekret") im Zusammenhang mit...
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share.
WALTHAM, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on July 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 35,750 shares of the Company’s common stock (“Stock Options”) and an aggregate of 79,050 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listi
SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.
Picton Mahoney Asset Management Announces Monthly Distribution for July 2026
This composite image, released on July 9, 2026, shows the region around a pulsar – a neutron star with a strong magnetic field that spins incredibly fast – within the Lighthouse nebula. The image contains X-ray data from NASA’s Chandra X-ray Observatory in purple, X-rays from NASA’s IXPE (Imaging X-ray Polarimetry Explorer) in blue, and […]
EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 14, 2026, the compensation committee of the Company’s board of directors granted six new non-executive employees 37,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
CAMBRIDGE, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on July 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).